We're celebrating a significant win for tamariki and rangatahi living with type 1 diabetes in Aotearoa. Pharmac's decision to fund continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables, starting 1 October 2024, marks a monumental step forward in ensuring equitable access to life-changing diabetes care.
As the Paediatric Society of New Zealand (PSNZ), we have advocated for improved access to these essential technologies. Our submission to the government highlighted the urgent need to support our youngest and most vulnerable, and today's announcement is a powerful acknowledgement of the importance of this cause.
This funding will have a profound impact on the lives of thousands of young people and their whānau. With approximately 12,000 individuals expected to benefit from CGMs in the first year and nearly 10,000 using insulin pumps within five years, this decision will not only improve health outcomes but also enhance the quality of life for so many.
Chair of our National Clinical Network for Children and Young People with Diabetes, Dr Jo McClintock, says: “Our pēpi, tamariki, and rangatahi with type 1 diabetes are unlikely to see anything more important than this decision in their lifetime. The impact of having this technology available for the parents and loved ones of young people with type 1 diabetes is going to be immeasurable – there will be lots of happy tears within whānau today.”
Having access to these tools means better health, more freedom, and reduced anxiety around managing diabetes. It's a game-changer, offering a brighter, healthier future.
We extend our heartfelt thanks to everyone who played a role in achieving this milestone. This is a momentous occasion for the type 1 diabetes community, and we are proud to stand with them.
Ngā mihi nui,
Paediatric Society of New Zealand | Te Kāhui Mātai Arotamariki o Aotearoa
